Zobrazeno 1 - 10
of 2 805
pro vyhledávání: '"canakinumab"'
Autor:
Armando Santoro, Garrido Pilar, Daniel S.W. Tan, Jon Zugazagoitia, Frances A. Shepherd, Alessandra Bearz, Fabrice Barlesi, Tae Min Kim, Tobias R. Overbeck, Enriqueta Felip, Can Cai, Eddy Simantini, Tracey McCulloch, Eric S. Schaefer
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-11 (2024)
Abstract Background Despite promising outcomes of treatment with anti-programmed cell death (PD)-1/PD-ligand (L)1 agents in combination with platinum-doublet chemotherapy (PDC) in the first-line setting, a significant unmet medical need remains in pa
Externí odkaz:
https://doaj.org/article/49d4a4474e494f5081ff231d7fc7b4f8
Autor:
Xiaona Zhu, Jiaqi Fan, Yanyan Huang, Yongbin Xu, Zhi Yang, Ruohang Weng, Ying Luo, Jun Yang, Tingyan He
Publikováno v:
Pediatric Rheumatology Online Journal, Vol 22, Iss 1, Pp 1-9 (2024)
Abstract Objective Cryopyrin-associated periodic syndrome (CAPS) is characterized by excessive IL-1β release resulting in systemic and organ inflammation. As an anti-IL-1 agent, canakinumab has been approved with all CAPS phenotypes in USA and Europ
Externí odkaz:
https://doaj.org/article/1c530000a23649069ebc8f0729c3f6be
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-7 (2024)
Abstract Cryopyrin-associated periodic syndromes (CAPS) are orphan hereditary auto-inflammatory diseases with various phenotypes, including chronic kidney disease (CKD). Current therapies inhibit interleukin-1 (IL-1) to achieve clinical and serologic
Externí odkaz:
https://doaj.org/article/347a47ff0dfc460c838a5fc516c0e003
Autor:
Łukasz Wołowiec, Walery Zukow, Julia Pęcherz, Daria Czaplińska, Albert Jaśniak, Grzegorz Grześk
Publikováno v:
Journal of Education, Health and Sport, Vol 65 (2024)
This article examines the role of inflammation in heart failure pathogenesis and explores novel therapeutic strategies targeting inflammatory pathways. The increasing prevalence of heart failure, particularly those with preserved ejection fraction (H
Externí odkaz:
https://doaj.org/article/57e85d6fa92948cba3a126f0b0cf9d28
Publikováno v:
Современная ревматология, Vol 18, Iss 2, Pp 25-32 (2024)
Objective: to present the experience of diagnosis, management and therapy with interleukin-1 inhibitors (iIL1) in patients with Chronic Infantile Onset Neurologic Cutaneous Articular/Neonatal Onset Multisystem Inflammatory Disease (CINCA/NOMID) accor
Externí odkaz:
https://doaj.org/article/ca0c0048906b4d11a43fc1a3b2e69527
Autor:
Isabelle Koné-Paut, Sophie Georgin-Lavialle, Alexandre Belot, Magali Jover, Mathilde Pouriel, Laure Lacoin, Pascal Pillet, Véronique Hentgen
Publikováno v:
Arthritis Research & Therapy, Vol 26, Iss 1, Pp 1-10 (2024)
Abstract Background Our study aimed to provide real-world evidence on the treatment patterns, effectiveness and safety of canakinumab in France in Familial Mediterranean Fever (FMF), Mevalonate Kinase Deficiency (MKD), and Tumor necrosis factor Recep
Externí odkaz:
https://doaj.org/article/34c48c38b9ac42039c8378778b84be14
Publikováno v:
Pediatric Rheumatology Online Journal, Vol 22, Iss 1, Pp 1-10 (2024)
Abstract Background Systemic juvenile idiopathic arthritis (sJIA) is a severe form of juvenile arthritis that is characterized by chronic joint inflammation and systemic symptoms such as fever, rash, and organ involvement. Anti-IL-6 receptor monoclon
Externí odkaz:
https://doaj.org/article/0a6df06d6f834ca192af351ee0176a79
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
S. O. Salugina, A. V. Torgashina, E. Yu. Borzova, V. V. Rameev, V. R. Gorodetskiy, E. S. Fedorov, N. V. Muravyeva
Publikováno v:
Научно-практическая ревматология, Vol 61, Iss 6, Pp 711-722 (2024)
The aim – to present the experience of diagnosis, management, and therapy with IL-1 inhibitors in patients with Schnitzler’s syndrome (SchS) according to a multicenter Russian cohort.Materials and methods. In an observational retrospective study
Externí odkaz:
https://doaj.org/article/3ef03064569c46a69d9d20a51383e7e4